Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Drug Safety Report Details 49,000 Undisclosed Side Effect Reports

September 10, 2014 1:45 pm | News | Comments

Healthcare informatics company AdverseEvents Inc. released a special drug safety report that includes an analysis of 48,971 unreleased FAERS reports. Read more...                         

TOPICS:

Antibiotics Do Not Shorten TB Treatment, Trial Finds

September 10, 2014 10:45 am | News | Comments

The results of a Phase 3 clinical trial, called REMoxTB, has found that replacing one of the drugs with the antibiotic moxifloxacin in the standard six-month treatment regimen did not allow the treatment time for TB patients to be shortened to four months. Read more...

TOPICS:

Nutrient Combo May be 'Super Pill' to Treat Depression

September 10, 2014 10:41 am | News | Comments

A new study will help people suffering from clinical depression by offering them new combination of nutrient-based medications to enhance mood. Read more...                           

TOPICS:
Advertisement

FDA Committee Votes Against Actavis Hypertension Drug

September 10, 2014 10:31 am | News | Comments

Actavis confirmed that the FDA Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis' NDA for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. Read more...   

TOPICS:

Sleep, Anxiety Meds May Increase Alzheimer's Risk

September 10, 2014 10:23 am | News | Comments

Taking benzodiazepines (widely prescribed drugs to treat anxiety and insomnia) is associated with an increased risk of developing Alzheimer's disease, particularly for long-term users, suggests a new study. Read more...         

TOPICS:

EC Grants Marketing Authorization for Lilly-BI Insulin

September 10, 2014 9:28 am | News | Comments

The European Commission (EC) granted marketing authorization for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged two years and above. Read more...    

TOPICS:

Auxilium to Cut 30% of Workforce

September 10, 2014 9:00 am | News | Comments

Auxilium Pharmaceuticals said Tuesday it is cutting 30 percent of its workforce, about 190 jobs, as part of a restructuring of its operations that will save it at least $75 million a year. The moves come as the company struggles with sales of its testosterone replacement gel Testim. Read more...

TOPICS:

Kinex Completes Acquisition of QuaDPharma

September 9, 2014 3:09 pm | News | Comments

Kinex Pharmaceuticals Inc. announced that it has completed the acquisition of QuaDPharma LLC, a Western New York based privately-held company specializing in pharmaceutical manufacturing, analytical and support services to the pharmaceutical and biotech industries. Read more...

TOPICS:
Advertisement

Galena Begins Phase 2 GALE-401 Trial

September 9, 2014 3:04 pm | News | Comments

Galena Biopharma Inc. announced the first patient has been dosed in the GALE-401, or Anagrelide Controlled Release (CR), Phase 2 clinical trial, which will treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs). Read more...

TOPICS:

Pharmatech, Weill Cornell Medical College Form Oncology Collaboration

September 9, 2014 2:58 pm | News | Comments

Pharmatech, Weill Cornell Medical College (WCMC) and 25 other leading oncology practices have agreed to evaluate an innovative program for rapidly identifying and enrolling patients in oncology clinical trials. Read more...        

TOPICS:

Par Pharmaceutical Resumes Shipment of Generic Precedex

September 9, 2014 2:50 pm | News | Comments

Par Pharmaceutical Companies Inc. announced that it has resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL, the generic version of Hospira’s Precedex Injection. Read more...             

NIAAA Conducting Trial of New Medication for Alcohol Use Disorder

September 9, 2014 2:46 pm | News | Comments

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) will conduct a clinical trial of gabapentin enacarbil as a potential treatment for alcohol use disorder (AUD). NIAAA estimates that the six-month trial will begin in the first half of 2015 and will enroll approximately 350 participants. Read more...    

TOPICS:

The Search for Ebola Immune Response Targets

September 9, 2014 2:38 pm | News | Comments

The effort to develop therapeutics and a vaccine against the deadly Ebola virus disease (EVD) requires a complex understanding of the microorganism and its relationship within the host, especially the immune response. Read more...       

BI COPD Combo Excels in Phase 3

September 9, 2014 11:27 am | News | Comments

Boehringer Ingelheim presented the first data from the pivotal Phase 3 TONADO 1&2 studies (NCT01431274/NCT01431287) for the fixed-dose combination (FDC) of tiotropium plus olodaterol delivered via the Respimat inhaler in patients with moderate to very severe chronic obstructive pulmonary disease. Read more...

TOPICS:

Researchers ID New Genetic Target for a Different Kind of Cancer Drug

September 9, 2014 11:13 am | News | Comments

Researchers have discovered that the protein RBM4, a molecule crucial to the process of gene splicing, is drastically decreased in multiple forms of human cancer, including lung and breast cancers. Read more...            

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading